News articles about MYOS RENS Technology (NASDAQ:MYOS) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MYOS RENS Technology earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.5359086476063 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Shares of MYOS RENS Technology (NASDAQ MYOS) traded up $0.02 during mid-day trading on Wednesday, hitting $1.56. 110,900 shares of the stock traded hands, compared to its average volume of 125,570. MYOS RENS Technology has a twelve month low of $1.12 and a twelve month high of $6.00. The company has a market capitalization of $9.77, a PE ratio of -2.36 and a beta of 1.47.
MYOS RENS Technology (NASDAQ:MYOS) last announced its quarterly earnings results on Tuesday, November 14th. The company reported ($0.13) EPS for the quarter. MYOS RENS Technology had a negative net margin of 941.41% and a negative return on equity of 71.14%. The firm had revenue of $0.16 million during the quarter.
TRADEMARK VIOLATION WARNING: “MYOS RENS Technology (MYOS) Earns News Impact Score of 0.05” was first published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-myos-rens-technology-myos-stock-price/1822951.html.
About MYOS RENS Technology
MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Receive News & Ratings for MYOS RENS Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology and related companies with MarketBeat.com's FREE daily email newsletter.